A pilot study on the impact of congenital thrombophilia in COVID‐19

Abstract

Complex interactions between various processes underlie the strong propensity for thrombosis in COVID-19 patients, but the individual circumstances that predispose to these complications have to date not been clearly established. ongenital thrombophilia is associated with early and recurrent thrombosis. Both, severe thrombophilic defects (deficiency of antithrombin, protein C and protein S) and mild prothrombotic polymorphisms (mainly FV Leiden and prothrombin G20210A) significantly increase the risk of thrombosis, particularly if combined with additional factors. 2 Thus, inherited thrombophilia might contribute to the increased risk of thrombosis in COVID-19 patients as suggested in some reviews or editorials. 3 However, in the analysis of bibliographical sources obtained from PubMed (January 2021) with the terms 'COVID-19' and 'thrombosis', no single study contains information concerning congenital thrombophilia apart from the description of a palmar digital vein thrombosis in a patient who was heterozygous for FV Leiden. he aim of our study was to investigate the association between inherited thrombophilias and COVID-19 manifestations and severity.